

# ISMP Oxytocin Medication Safety Best Practices

May 19<sup>th</sup>, 2022

Logan Moore, PharmD

PGY-2 Medication-Use Safety and Policy Resident

### **Objectives**



Review the five event themes associated with oxytocin



Summarize the ISMP Targeted Medication Safety Best Practices (TMSBP) 2022-2023 recommendations for oxytocin



# Oxytocin (Pitocin®)

- **Common Indications:** Induction or stimulation of labor, postpartum uterine bleeding, termination of pregnancy
- Supplied As: 10 units/mL (various volumes available)
- Precautions: Improper administration can cause hyperstimulation of the uterus, which in turn can result in fetal distress, the need for an emergency cesarean section, or uterine rupture
  - A few maternal, fetal, and neonatal deaths have been reported because of oxytocin errors



## **History of Reported Errors**

- ISMP analyzed voluntary error reports submitted between <u>1999 and 2019</u>
  - During that time, 52 reports involved oxytocin:
    - 10% described ≥ 1 oxytocin error
    - 44% originated during dispensing
    - 23% originated during the administration
    - 13% originated during prescribing
    - 25% resulted in maternal, fetal, or neonatal harm



## Five Event Themes Associated with Oxytocin

### Prescribing errors

• (e.g., ordering oxyCODONE and accidentally selecting oxytocin)

### Look-alike drug packaging and names

• (e.g., Pitocin<sup>®</sup> and Pitressin<sup>®</sup>, both referred to as "pit")

### Preparation challenges

(e.g., unlabeled infusion bags)

#### Administration-associated errors

• (e.g., concentration milliunits per mL or units per L)

### Communication gaps

(e.g., conflicting orders during change of shift)



# ISMP's Targeted Medication Safety Best Practices (TMSBP) for Hospitals and Survey

- Targeted for the hospital setting; applicable to other healthcare settings
- Survey:
  - Hospitals participated (N = 188):
    - ≥ 500 beds (30%)
    - 300-499 beds (21%)
    - 100-299 beds (27%)
    - 26-99 beds (16%)
  - > 66% report having part or full-time medication safety officer(s) (MSO)

- 1. Require the use of **standard order sets** to prescribe for labor induction/ augmentation and control of postpartum bleeding
  - 83% full implementation
  - Barriers: Anesthesia staff resistance, allowing prescribers to bypass order sets, accepting free-text orders
  - Enabler: Systemwide standard order set, leadership requiring its use



- 2. Standardize to **single concentration/bag size** for antepartum and postpartum infusions (e.g., 30 units in 500 mL)
  - 84% full implementation
  - Barriers: Anesthesia staff resistance to single concentration for both indications
  - Enabler: Single concentration in CPOE & infusion pump drug library
  - Most respondents report using 30 units/500 mL standardized concentration



- 3. Standardize how doses, concentration & rates are **expressed** & communicate orders in dose rate aligned with smart infusion pump DFRS
  - 80% full implementation of standard of expression
  - 82% orders in dose rate, aligning with DERS
  - Barriers: Allowing different dosing based on indication & excluding oxytocin from infusion pump interoperability due to workflow challenges
  - **Enablers:** Standardize dosing units & concentration in orders sets & smart pump drug library



- 4. Provide oxytocin in **ready-to-use form**. Boldly label both sides of infusion bag to differentiate oxytocin bags from hydrating & magnesium infusions
  - 86% have ready-to-use form
  - 36% labeling both sides of the infusion bag
  - Barriers: Unavailability of premixed bags and "supply issues"
  - Enablers: Require pharmacy to prepare all infusions & purchase premixed infusions



#### 2022-2023

- 5. Avoid bringing oxytocin infusion bags to the patient's bedside **until** prescribed & needed
  - 57% full implementation

### • Barriers:

- Nursing staff shortages
- Nursing preference to have emergency medications in the patient's room
- Inability to leave patient to retrieve oxytocin infusion



### Summary



Precautions must be taken with use of oxytocin to prevent maternal, fetal, and neonatal harm



ISMP's TMSBP 2022-2023 oxytocin recommendations can mitigate identified challenges associated with the medication



Limitations to survey results include small sample size





# Questions?

May 19<sup>th</sup>, 2022

Logan Moore, PharmD

PGY-2 Medication-Use Safety and Policy Resident